mRNA Therapeutics Market Research Report
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on MRNA Therapeutics Market
5.1. COVID-19 Landscape: MRNA Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global MRNA Therapeutics Market, By Application
8.1. MRNA Therapeutics Market, by Application,
8.1.1 Rare Genetic Diseases
8.1.1.1. Market Revenue and Forecast
8.1.2. Oncology
8.1.2.1. Market Revenue and Forecast
8.1.3. Respiratory Diseases
8.1.3.1. Market Revenue and Forecast
8.1.4. Infectious Diseases
8.1.4.1. Market Revenue and Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Forecast
Chapter 9. Global MRNA Therapeutics Market, By Type
9.1. MRNA Therapeutics Market, by Type,
9.1.1. Prophylactic Vaccines
9.1.1.1. Market Revenue and Forecast
9.1.2. Therapeutic Vaccines
9.1.2.1. Market Revenue and Forecast
9.1.3. Therapeutic Drugs
9.1.3.1. Market Revenue and Forecast
Chapter 10. Global MRNA Therapeutics Market, By End-use
10.1. MRNA Therapeutics Market, by End-use,
10.1.1. Hospitals & Clinics
10.1.1.1. Market Revenue and Forecast
10.1.2. Research Organizations
10.1.2.1. Market Revenue and Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Forecast
Chapter 11. Global MRNA Therapeutics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Application
11.1.2. Market Revenue and Forecast, by Type
11.1.3. Market Revenue and Forecast, by End-use
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Application
11.1.4.2. Market Revenue and Forecast, by Type
11.1.4.3. Market Revenue and Forecast, by End-use
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Application
11.1.5.2. Market Revenue and Forecast, by Type
11.1.5.3. Market Revenue and Forecast, by End-use
11.2. Europe
11.2.1. Market Revenue and Forecast, by Application
11.2.2. Market Revenue and Forecast, by Type
11.2.3. Market Revenue and Forecast, by End-use
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Application
11.2.4.2. Market Revenue and Forecast, by Type
11.2.4.3. Market Revenue and Forecast, by End-use
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Application
11.2.5.2. Market Revenue and Forecast, by Type
11.2.5.3. Market Revenue and Forecast, by End-use
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Application
11.2.6.2. Market Revenue and Forecast, by Type
11.2.6.3. Market Revenue and Forecast, by End-use
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Application
11.2.7.2. Market Revenue and Forecast, by Type
11.2.7.3. Market Revenue and Forecast, by End-use
11.3. APAC
11.3.1. Market Revenue and Forecast, by Application
11.3.2. Market Revenue and Forecast, by Type
11.3.3. Market Revenue and Forecast, by End-use
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Application
11.3.4.2. Market Revenue and Forecast, by Type
11.3.4.3. Market Revenue and Forecast, by End-use
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Application
11.3.5.2. Market Revenue and Forecast, by Type
11.3.5.3. Market Revenue and Forecast, by End-use
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Application
11.3.6.2. Market Revenue and Forecast, by Type
11.3.6.3. Market Revenue and Forecast, by End-use
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Application
11.3.7.2. Market Revenue and Forecast, by Type
11.3.7.3. Market Revenue and Forecast, by End-use
11.4. MEA
11.4.1. Market Revenue and Forecast, by Application
11.4.2. Market Revenue and Forecast, by Type
11.4.3. Market Revenue and Forecast, by End-use
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Application
11.4.4.2. Market Revenue and Forecast, by Type
11.4.4.3. Market Revenue and Forecast, by End-use
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Application
11.4.5.2. Market Revenue and Forecast, by Type
11.4.5.3. Market Revenue and Forecast, by End-use
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Application
11.4.6.2. Market Revenue and Forecast, by Type
11.4.6.3. Market Revenue and Forecast, by End-use
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Application
11.4.7.2. Market Revenue and Forecast, by Type
11.4.7.3. Market Revenue and Forecast, by End-use
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Application
11.5.2. Market Revenue and Forecast, by Type
11.5.3. Market Revenue and Forecast, by End-use
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Application
11.5.4.2. Market Revenue and Forecast, by Type
11.5.4.3. Market Revenue and Forecast, by End-use
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Application
11.5.5.2. Market Revenue and Forecast, by Type
11.5.5.3. Market Revenue and Forecast, by End-use
Chapter 12. Company Profiles
12.1. Moderna, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. BioNTech SE
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. CureVac N.V.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Arcturus Therapeutics
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Translate Bio, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. GSK plc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Argos Therapeutics Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Sangamo Therapeutics, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Pfizer Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. AstraZeneca plc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers